Study on recurrence prevention therapy with dienogest after laparoscopic surgery for endometriosis

Capa

Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

Objective: To assess the incidence of adverse drug reactions in women taking dienogest after surgical treatment of endometriosis and to determine the influence of baseline clinical and demographic characteristics on discontinuation of recurrence prevention therapy in the postoperative period.

Materials and methods: The study included 48 female patients who underwent surgical treatment for endometriosis and received recurrence prevention therapy with dienogest for 120 days between January and March 2024.

Results: There were 38/48 (79.2%) patients who completed the full course of dienogest therapy for 120 days and 10/48 (20.8%) patients who had to discontinue therapy due to the development of undesirable adverse reactions to dienogest. The leading causes for discontinuing dienogest therapy were abnormal uterine bleeding in 6/48 (12.5%) patients and migraine in 5/48 (10.4%). Psychiatric side effects were also experienced by 5/48 (11.6%) patients, with symptoms including depressive disorders, emotional instability and cognitive impairment.

Conclusion: Regardless of age, body mass index or clinical indicators of endometriosis, the use of dienogest may be associated with a risk of adverse drug reactions and may lead to the discontinuation of recurrence prevention therapy.

Texto integral

Acesso é fechado

Sobre autores

Svetlana Dubrovina

Rostov State Medical University, Ministry of Health of Russia

Autor responsável pela correspondência
Email: s.dubrovina@gmail.com

Professor, Dr. Med. Sci., Chief Researcher, Obstetrics and Pediatrics Research Institute, Professor at the Department of Obstetrics and Gynecology No. 1, RostSMU, Ministry of Health of Russia

Rússia, Rostov-on-Don

Marina Vovkochina

Rostov State Medical University, Ministry of Health of Russia

Email: jordan-85@inbox.ru

obstetrician-gynecologist at the Obstetrics and Pediatrics Research Institute

Rússia, Rostov-on-Don

Yulia Berlim

Rostov-on-Don City Hospital No. 6

Email: juliaberlim@yandex.ru

PhD, Deputy Chief Physician for the Medical Affairs

Rússia, Rostov-on-Don

Diana Bogunova

Rostov State Medical University, Ministry of Health of Russia

Email: bogunovadi@yandex.ru

obstetrician-gynecologist at the Obstetrics and Pediatrics Research Institute

Rússia, Rostov-on-Don

Anna Alexandrina

Rostov-on-Don City Emergency Hospital

Email: anna221215@inbox.ru

obstetrician-gynecologist

Rússia, Rostov-on-Don

Daria Bozhinskaya

Rostov State Medical University, Ministry of Health of Russia; Rostov-on-Don City Hospital No. 6

Email: dasha.bozhinskaya@yandex.ru

Resident at the Department of Obstetrics and Gynecology No. 1, trainee obstetrician-gynecologist

Rússia, Rostov-on-Don; Rostov-on-Don

Bibliografia

  1. International Working Group of AAGL, ESGE, ESHRE and WES, Tomassetti C., Johnson N.P., Petrozza J., Abrao M.S., Einarsson J.I., Horne A.W. et al. An international terminology for endometriosis, 2021. Hum. Reprod. Open. 2021; 2021(4): hoab029. https://dx.doi.org/10.1093/hropen/hoab029
  2. Smolarz B., Szyłło K., Romanowicz H. Endometriosis: epidemiology, classification, pathogenesis, treatment and genetics (review of literature). Int. J. Mol. Sci. 2021; 22(19): 10554. https://dx.doi.org/10.3390/ ijms221910554.
  3. Missmer S.A., Hankinson S.E., Spiegelman D., Barbieri R.L., Marshall L.M., Hunter D.J. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am. J. Epidemiol. 2004; 160(8): 784-96. https://dx.doi.org/10.1093/aje/kwh275.
  4. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. 2024. [Ministry of Health of the Russian Federation. Clinical guidelines. Endometriosis. 2024. (in Russian)].
  5. Улумбекова Г.Э., Худова И.Ю. Оценка демографического, социального и экономического эффекта применения гормональной терапии при эндометриозе и аномальных маточных кровотечениях. ОРГЗДРАВ: новости, мнения, обучение. Вестник ВШОУЗ. 2022; 8(1): 82-113. [Ulumbekova G.E., Khudova I.Yu. Demographic, social and economic effect of hormonal therapy in endometriosis and abnormal uterine bleeding. HEALTH CARE MANAGEMENT: News, Views, Education. Bulletin of VSHOUZ. 2022; 8(1): 82-113 (in Russian)]. https://dx.doi.org/10.33029/2411-8621-2022-8-1-82-113
  6. Agarwal S.K., Chapron C., Giudice L.C., Laufer M.R., Leyland N., Missmer S.A. et al. Clinical diagnosis of endometriosis: a call to action. Am. J. Obstet. Gynecol. 2019; 220(4): 354.e1-354.e12. https://dx.doi.org/10.1016/ j.ajog.2018.12.039
  7. Centini G., Lazzeri L., Dores D., Pianigiani L., Iannone P., Luisi S. et al. Chronic pelvic pain and quality of life in women with and without endometriosis. J. Endometr. Pelvic Pain Disord. 2013; 5(1): 27-33. https://dx.doi.org/10.5301/JE.5000148
  8. Strathy J.H., Molgaard C.A., Coulam C.B., Melton L.J. 3rd. Endometriosis and infertility: a laparoscopic study of endometriosis among fertile and infertile women. Fertil. Steril. 1982; 38(6): 667-72. https://dx.doi.org/10.1016/ s0015-0282(16)46691-4
  9. Адамян Л.В., Андреева Е.Н. Эндометриоз и его глобальное влияние на организм женщины. Проблемы репродукции. 2022; 28(1): 54-64. [Adamyan L.V., Andreeva E.N. Endometriosis and its global impact on a woman’s body. Russian Journal of Human Reproduction. 2022; 28(1): 54-64. (in Russian)]. https://dx.doi.org/10.17116/ repro20222801154
  10. Di Donato N., Montanari G., Benfenati A., Monti G., Leonardi D., Bertoldo V. et al. Sexual function in women undergoing surgery for deep infiltrating endometriosis: a comparison with healthy women. J. Fam. Plann. Reprod. Health Care. 2015; 41(4): 278-83.
  11. Daniilidis A., Angioni S., Di Michele S., Dinas K., Gkrozou F., D'Alterio M.N. Deep endometriosis and infertility: what is the impact of surgery? J. Clin. Med. 2022; 11(22): 6727. https://dx.doi.org/10.3390/ jcm11226727
  12. Lazzeri L., Orlandini C., Vannuccini S., Pinzauti S., Tosti C., Zupi E. et al. Endometriosis and perceived stress: impact of surgical and medical treatment. Gynecol. Obstet. Investig. 2015; 79(4): 229-33. https:// dx.doi.org/10.1159/000368776
  13. Vincent K., Kennedy S., Stratton P. Pain scoring in endometriosis: entry criteria and outcome measures for clinical trials. Report from the Art and Science of Endometriosis meeting. Fertil. Steril. 2010; 93(1): 62-7. https://dx.doi.org/10.1016/j.fertnstert.2008.09.056
  14. Дубровина С.О., Берлим Ю.Д., Александрина А.Д., Вовкочина М.А., Богунова Д.Ю., Гимбут В.С., Божинская Д.М. Современные представления о диагностике и лечении эндометриоза. Акушерство и гинекология. 2023; 2: 146-53. [Dubrovina S.O., Berlim Yu.D., Aleksandrina A.D., Vovkochina M.A., Bogunova D.Yu., Gimbut V.S., Bozhinskaya D.M. Modern ideas about the diagnosis and treatment of endometriosis. Obstetrics and Gynecology. 2023; (2): 146-53 (in Russian)]. https://dx.doi.org/ 10.18565/aig.2023.43
  15. Беженарь В.Ф., Круглов С.Ю., Кузьмина Н.С., Крылова Ю.С., Сергиенко А.С., Абилбекова А.К., Жемчужина Т.Ю. Целесообразность длительной гормональной терапии эндометриоза после хирургического лечения. Акушерство и гинекология. 2021; 4: 134-42. [Bezhenar V.F., Kruglov S.Yu., Kuzmina N.S., Krylova Yu.S., Sergienko A.S., Abilbekova A.K., Zhemchuzhina T.Yu. Effectiveness of long-term hormone therapy for endometriosis after surgical treatment. Obstetrics and Gynecology. 2021; (4): 134-42 (in Russian)]. https://dx.doi.org/10.18565/ aig.2021.4.134-142
  16. Sukhikh G.T., Adamyan L.V., Dubrovina S.O., Baranov I.I., Bezhenar V.F., Kozachenko A.V. et al. Prolonged cyclical and continuous regimens of dydrogesterone are effective for reducing chronic pelvic pain in women with endometriosis: results of the ORCHIDEA study. Fertil. Steril. 2021; 116(6): 1568-77. https://dx.doi.org/10.1016/j.fertnstert.2021.07.1194
  17. Chung H.F., Hayashi K., Dobson A.J., Sandin S., Ideno Y., Hardy R. et al. Association between endometriosis and type and age of menopause: a pooled analysis of 279 948 women from five cohort studies. Hum. Reprod. 2025: deaf068. https://dx.doi.org/10.1093/humrep/deaf068
  18. As-Sanie S., Mackenzie S.C., Morrison L., Schrepf A., Zondervan K.T., Horne A.W. et al. Endometriosis: a review. JAMA. 2025 May 5. https://dx.doi.org/10.1001/jama.2025.2975
  19. Li R.R., Xi Q., Tao L., Sheng W., Zhao C.C., Wu Y.J. A systematic review and Bayesian analysis of the adverse effects of dienogest. BMC Pharmacol Toxicol. 2024; 25(1): 43. ttps://dx.doi.org/10.1186/s40360-024-00767-1
  20. Kim S.E., Lim H.H., Lee D.Y., Choi D. The long-term effect of dienogeston bone mineral density after surgical treatment of endometrioma. Reprod. Sci. 2021; 28(5): 1556-62. https://dx.doi.org/10.1007/s43032-020-00453-7
  21. Nirgianakis K., Vaineau C., Agliati L., McKinnon B., Gasparri M.L., Mueller M.D. Risk factors for non-response and discontinuation of Dienogest in endometriosis patients: A cohort study. Acta Obstet. Gynecol. Scand. 2021; 100(1): 30-40. https://dx.doi.org/10.1111/aogs.13969
  22. Peng C., Huang Y., Zhou Y. Dydrogesterone in the treatment of endometriosis: evidence mapping and meta-analysis. Arch. Gynecol. Obstet. 2021; 304(1): 231-52. https://dx.doi.org/10.1007/s00404-020-05900-z
  23. Денисова Н.В., Перелыгина И.О., Клокова В.М. Применение дидрогестерона в комплексном лечении пациенток с эндометриомами яичников. Вопросы гинекологии, акушерства и перинатологии. 2025; 24(1): 172-6. [Denisova N.V., Perelygina I.O., Klokova V.M. Use of dydrogesterone in the complex treatment of patients with ovarian endometriomas. Gynecology, Obstetrics and Perinatology. 2025; 24(1): 172-6 (in Russian)]. https:// dx.doi.org/10.20953/1726-1678-2025-1-172-176
  24. Общая характеристика лекарственного препарата Дюфастон®, таблетки, покрытые пленочной оболочкой, 10 мг, ЛП-№(001546)-(РГ-RU). Доступно по: https://www.vidal.ru/drugs/duphaston__1048 [Summary of Product Characteristics of Dufaston® 10 mg Film-coated tablets, LD- No. (001546) - (RG-RU). Available at: www.vidal.ru/drugs/duphaston__1048 (in Russian)].
  25. Сухих Г.Т., Серов В.Н., Адамян Л.В., Баранов И.И., Беженарь В.Ф., Габидуллина Р.И., Дубровина С.О., Козаченко А.В., Подзолкова Н.М., Сметник А.А., Тапильская Н.И., Уварова Е.В., Ших Е.В., Ярмолинская М.И. Алгоритмы ведения пациенток с эндометриозом: согласованная позиция экспертов Российского общества акушеров-гинекологов. Акушерство и гинекология. 2023; 5: 159-76. [Sukhikh G.T., Serov V.N., Adamyan L.V., Baranov I.I., Bezhenar V.F., Gabidullina R.I., Dubrovina S.O., Kozachenko A.V., Podzolkova N.M., Smetnik A.A., Tapilskaya N.I., Uvarova E.V., Shikh E.V., Yarmolinskaya M.I. Algorithms for the management of patients with endometriosis: an agreed position of experts from the Russian Society of Obstetricians and Gynecologists. Obstetrics and Gynecology. 2023; (5): 159-76 (in Russian)]. https://dx.doi.org/10.18565/aig.2023.132

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar
2. Рисунок. Частота встречаемости нежелательных явлении диеногеста, послуживших причиной отказа от противорецидивной терапии эндометриоза

Baixar (111KB)
Metadados

Declaração de direitos autorais © Bionika Media, 2025